Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD

被引：0
|
作者：
Moens, A. [1 ,2 ]
Verstockt, B. [1 ,2 ]
Alsoud, D. [2 ]
Sabino, J. [1 ,2 ]
Ferrante, M. [1 ,2 ]
Vermeire, S. [1 ,2 ]
机构：
[1] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.433
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P309
引用
收藏
页码：S336 / S337
页数：4
相关论文
共 50 条
  • [41] A REAL LIFE COMPARISON OF THE EFFECTIVENESS OF ADALIMUMAB VERSUS GOLIMUMAB IN MODERATE-TO-SEVERE ULCERATIVE COLITIS. A MULTICENTRE EXPERIENCE FROM A REGIONAL NETWORK FOR INFLAMMATORY BOWEL DISEASE
    Renna, S.
    Mocciaro, F.
    Ventimiglia, M.
    Orlando, R.
    Macaluso, F. S.
    Cappello, M.
    Fries, W.
    Mendolaro, M.
    Privitera, A. C.
    Ferracane, C.
    Pisana, V.
    Magnano, A.
    Pluchino, D.
    Inserra, G.
    Scarpulla, G.
    Garufi, S.
    Carroccio, A.
    Siringo, S.
    Billeci, M.
    Dimitri, R.
    Cottone, M.
    Orlando, A.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E72 - E72
  • [42] Evaluating risankizumab for moderate-to-severe plaque psoriasis: real-world outcomes from an international study
    Bagit, Ahmed
    Maliyar, Khalad
    Mansour, Mark
    Georgakopoulos, Jorge
    Rankin, Brian
    Lytvyn, Yuliya
    Zaaroura, Hiba
    Park, Ye-Jean
    Wang, Emilie
    Mufti, Asfandyar
    Torres, Tiago
    Le, Ana Maria
    Vender, Ronald
    Prajapati, Vimal H.
    Yeung, Jensen
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [43] Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data
    Konikoff, Tom
    Yanai, Henit
    Libchik, Dror
    Avni-Biron, Irit
    Snir, Yifat
    Banai, Hagar
    Broytman, Yelena
    Dotan, Iris
    Ollech, Jacob E.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (13)
  • [44] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
  • [45] Vedolizumab is superior to anti-tumor necrosis factor agents as a first-line biological agent but not as a second-line biological agent in moderate to severe ulcerative colitis
    Pudipeddi, A.
    Ko, Y.
    Paramsothy, S.
    Leong, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 136 - 136
  • [46] VEDOLIZUMAB IS SUPERIOR TO ANTI-TUMOR NECROSIS FACTOR AGENTS AS A FIRST-LINE BIOLOGICAL AGENT BUT NOT AS A SECOND-LINE BIOLOGICAL AGENT IN MODERATE TO SEVERE ULCERATIVE COLITIS
    Pudipeddi, Aviv
    Ko, Yanna
    Paramsothy, Sudarshan
    Leong, Rupert W.
    GASTROENTEROLOGY, 2021, 160 (06) : S343 - S343
  • [47] Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study
    Rigopoulos, Dimitrios
    Angelakopoulos, Charalampos
    Apalla, Zoi
    Georgiou, Sophia
    Delli, Florentina
    Drosos, Alexandros
    Zafiriou, Efterpi
    Katsantonis, John
    Lazaridou, Elisavet
    Panagakis, Pantelis
    Papadavid, Evangelia
    Papakonstantis, Markos
    Roussaki-Schulze, Angeliki-Viktoria
    Sotiriou, Elena
    Anastasiadis, Georgios
    Tampouratzi, Eleftheria
    Chasapi, Vasiliki
    Sfaelos, Konstantinos
    Ioannides, Dimitrios
    DERMATOLOGIC THERAPY, 2022, 35 (12)
  • [48] Initial report on the month 12 results from PSoHO for biologic-treated patients with moderate-to-severe psoriasis in the real-world setting
    Costanzo, Antonio
    Paul, Carle F.
    Carrascosa, Jose Manuel
    Tada, Yayoi
    Brnabic, Alan
    Schuster, Christopher
    Reed, Catherine
    Abrahamy, Michael
    Riedl, Elisabeth
    Pinter, Andreas
    Boecker, Ulrike
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 70 - 70
  • [49] STABLE PHARMACOKINETICS AND BIOCHEMICAL MARKERS OF IBD ACTIVITY: RESULTS FROM REAL-WORLD ADALIMUMAB BIOSIMILAR SWITCHING PROGRAM
    Moore, Alice
    Russell, David
    Dart, Robin
    Dias, Shiluka
    Ghuman, Sundeep
    Petri, Bianca
    Sharma, Esha
    Anderson, Simon
    Irving, Peter
    Samaan, Mark
    GUT, 2022, 71 : A59 - A60
  • [50] Risankizumab for the treatment of moderate-to-severe psoriasis: Real-world data from the Czech Republic BIOREP Registry
    Kojanova, Martina
    Fialova, Jorga
    Cetkovska, Petra
    Gkalpakiotis, Spyridon
    Machovcova, Alena
    Arenberger, Petr
    Stork, Jiri
    Dolezal, Tomas
    Strosova, Daniela
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB83 - AB83
12345